Latest Femasys Inc. Stories
ATLANTA, April 30, 2013 /PRNewswire/ -- Femasys Inc., a medical device developer of women's healthcare solutions, announced today the U.S. launch of the 510(k) cleared FemCerv(TM), an innovative endocervical curettage device. FemCerv is designed to collect a complete, non-contaminated tissue sample with minimal patient discomfort. Endocervical curettage has the potential for the detection of high-grade lesions or invasive cancer that may not be detected by other methods. Femasys...
ATLANTA, Nov. 20, 2012 /PRNewswire/ -- Femasys Inc., an emerging medical device developer of women's healthcare solutions, today announced that its President and Chief Executive Officer, Kathy Lee-Sepsick, has been invited to present at the 24(th) Annual Piper Jaffray Healthcare Conference being held in New York, NY. The presentation is scheduled for Wednesday, November 28, 2012 at 12:10 pm Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20110502/CL93858LOGO ) ABOUT...
ATLANTA, March 22, 2012 /PRNewswire/ -- Femasys Inc., an emerging medical device developer of women's healthcare solutions, today announced an agreement with Bayer Yakuhin, Ltd., Osaka, Japan, for exclusive distribution rights in Japan for Femasys' FemVue(TM) Saline-Air Device. This is the first device that allows physicians to quickly and effectively evaluate with ultrasound a woman's fallopian tubes, a critical component of her fertility assessment. The FemVue evaluation...
ATLANTA, Nov. 7, 2011 /PRNewswire/ -- Femasys Inc., an emerging medical device developer of women's healthcare solutions, announced today that it has received 510(k) clearance for the FemChec(TM) Pressure Management Device, the first device designed for a low pressure HSG as a confirmation test after a permanent sterilization procedure is performed. FemChec utilizes patent-pending technology that limits the applied intrauterine pressure to 200 mmHg, providing confidence to the physician...
SPARTANBURG, S.C., Aug. 16, 2011 /PRNewswire/ -- Femasys Inc. and Norgenix Pharmaceuticals, LLC today announced an agreement for exclusive distribution rights in the United States as well as US territories and military bases for Femasys' FemVue(TM) Saline-Air Device. This FDA cleared device is used to evaluate a woman's fallopian tubes with standard ultrasound, called a Sono HSG. Femasys Inc. is an emerging medical device developer of women's healthcare solutions. Norgenix Pharmaceuticals,...
ATLANTA, May 2, 2011 /PRNewswire/ --Femasys Inc., an emerging medical device developer of women's healthcare solutions, announced today the 510(k) clearance of FemVue(TM) Saline-Air Device for a diagnostic Sono HSG allowing physicians to evaluate a woman's fallopian tubes with existing ultrasound equipment. The product allows for a cost-effective, convenient, and safe (non-radiation) Sono HSG procedure to be performed quickly by a woman's gynecologist or infertility specialist in the...
